It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

Abby Smith, 40, a NHS manager from Reading, has the rare autoimmune disease myasthenia gravis, which means she needs her ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

But one of the rarest muscular disorders is also one of the most concerning. It's called myasthenia gravis and affects only about 37 out of every 100,000 people in the United States. Despite being ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

Muscle weakness and fatigue may make daily activities more difficult. Take a closer look at what is happening.­ Learn about gMG and a treatment in this video.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

USA-based healthcare giant Johnson & Johnson has announced the publication of key Phase III data for nipocalimab in The Lancet Neurology. J&J is testing the investigational FcRn blocker in a broad ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.